AbCellera Biologics (ABCL)
NASDAQ:ABCL
ABCL Stock Chart & Stats
$3.54
-$0.28(-8.54%)
At close: 4:00 PM EST
$3.54
-$0.28(-8.54%)
Day’s Range― - ―
52-Week Range$1.94 - $6.52
Previous CloseN/A
Volume1.71M
Average Volume (3M)2.61M
Market Cap
$1.07B
Enterprise Value$1.06B
Total Cash (Recent Filing)$560.33M
Total Debt (Recent Filing)$143.22M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 11, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding303,160,500
10 Day Avg. Volume2,504,148
30 Day Avg. Volume2,609,167
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)0.90
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue14.13
Enterprise Value/Gross Profit14.13
Enterprise Value/Ebitda-6.06
Forecast
1Y Price Target
$8.75Price Target Upside147.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$30.54M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationPositive proof-of-concept data for ABCL635 could validate the strategic shift toward internally developed candidates and materially reduce clinical development risk in investor assessments.
Commercial OpportunityStrong willingness from key opinion leaders to prescribe a safe, self‑administered subcutaneous antibody implies a sizable addressable market among patients who cannot take hormonal therapy and supports high commercial upside if efficacy is demonstrated.
Financial FlexibilityA solid cash position, supported by licensing revenues and a patent settlement, provides runway for internal programs and enhances the company's ability to pursue partnerships and milestone-driven upside.
Bears Say
Analyst Conflict RiskA disclosed conflict of interest at a research firm may undermine confidence in analyst reports and increase stock volatility due to perceived bias in published assessments.
Clinical Benchmark RiskUpcoming clinical results will be compared to established therapies, creating a demanding efficacy hurdle that could hurt valuation if the data falls short of market expectations.
Revenue Transition RiskManagement's move to prioritize the internal pipeline is expected to reduce research fee revenue, creating near-term revenue headwinds before new program milestones can generate offsetting income.
AbCellera Biologics News
ABCL FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was $1.94 and its highest was $6.51 in the past 12 months.
What is AbCellera Biologics’s market cap?
AbCellera Biologics’s market cap is $1.07B.
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is May 11, 2026 which is in 28 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Feb 24, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.104.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -0.16.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 303,160,500 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went down -0.932%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (147.18% Upside)
$8.75 (147.18% Upside)
Blogger Sentiment
Neutral
ABCL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $856.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
71.01%
12-Months-Change
Fundamentals
Return on Equity
-14.16%
Trailing 12-Months
Asset Growth
-0.26%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful progress in AbCellera's strategic transition to a clinical-stage biotech: solid liquidity (~$700M available), completion of platform and manufacturing investments, successful nomination and clinic advancement of multiple internal candidates, and a roadmap of near- and mid-term clinical catalysts (notably ABCL635 Phase II readout in Q3 2026). At the same time, notable risks and near-term challenges were acknowledged: revenue growth in 2025 was materially influenced by a one-time legal settlement, research fee revenues are expected to decline as the company pivots to internal programs, R&D spending and cash burn remain elevated, and lead programs face clinical and class-specific safety uncertainties that could delay value realization. Overall, the positive operational and pipeline milestones and strong liquidity outweigh the near-term financial and clinical risks.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$8.75
▲(147.18% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
41.17% Insiders
4.71% Mutual Funds
18.40% Other Institutional Investors
34.38% Public Companies and Individual Investors